These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2977339)

  • 21. Evaluation of skin test reactions in patients with non-immediate type drug eruptions.
    Osawa J; Naito S; Aihara M; Kitamura K; Ikezawa Z; Nakajima H
    J Dermatol; 1990 Apr; 17(4):235-9. PubMed ID: 2142173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981-1985).
    Alanko K; Stubb S; Kauppinen K
    Acta Derm Venereol; 1989; 69(3):223-6. PubMed ID: 2566225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions.
    Waton J; Tréchot P; Loss-Ayav C; Schmutz JL; Barbaud A
    Br J Dermatol; 2009 Apr; 160(4):786-94. PubMed ID: 19120340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is drug allergy less prevalent than previously assumed? A 5-year analysis.
    Heinzerling LM; Tomsitz D; Anliker MD
    Br J Dermatol; 2012 Jan; 166(1):107-14. PubMed ID: 21916887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed drug eruption: state of the art.
    Ozkaya E
    J Dtsch Dermatol Ges; 2008 Mar; 6(3):181-8. PubMed ID: 18076661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests.
    Soria A; Barbaud A; Assier H; Avenel-Audran M; Tétart F; Raison-Peyron N; Amarger S; Girardin P; Francès C;
    Dermatology; 2015; 231(4):353-9. PubMed ID: 26457932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of skin testing in the investigation of cutaneous adverse drug reactions.
    Barbaud A; Reichert-Penetrat S; Tréchot P; Jacquin-Petit MA; Ehlinger A; Noirez V; Faure GC; Schmutz JL; Béné MC
    Br J Dermatol; 1998 Jul; 139(1):49-58. PubMed ID: 9764148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-specific clinical pattern in fixed drug eruptions.
    Thankappan TP; Zachariah J
    Int J Dermatol; 1991 Dec; 30(12):867-70. PubMed ID: 1840060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous adverse drug reactions: enhanced imputation score by skin testing].
    Choquet-Kastylevsky G; Vial T; Santolaria N; Nageotte A; Faure M; Claudy A; Descotes J
    Ann Dermatol Venereol; 2001 Apr; 128(4):507-11. PubMed ID: 11395648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Skin and mucous membrane manifestations in the use of clonazepam].
    Bernard K
    Lijec Vjesn; 1986 May; 108(5):235-6. PubMed ID: 2941631
    [No Abstract]   [Full Text] [Related]  

  • 31. Fixed drug eruption following metronidazole therapy and the use of topical provocation testing in diagnosis.
    Short KA; Fuller LC; Salisbury JR
    Clin Exp Dermatol; 2002 Sep; 27(6):464-6. PubMed ID: 12372086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin tests in the diagnosis of eruptions caused by betalactams.
    Lisi P; Lapomarda V; Stingeni L; Assalve D; Hansel K; Caraffini S; Agostinelli D
    Contact Dermatitis; 1997 Oct; 37(4):151-4. PubMed ID: 9385509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The usefulness of skin tests to prove drug hypersensitivity.
    Lammintausta K; Kortekangas-Savolainen O
    Br J Dermatol; 2005 May; 152(5):968-74. PubMed ID: 15888154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of modified skin and provocation tests with drugs for the specific diagnosis of drug allergy occurring with a skin lesion].
    Borodin IuP; Dokhnenko AM
    Vestn Dermatol Venerol; 1979 Apr; (4):33-7. PubMed ID: 155365
    [No Abstract]   [Full Text] [Related]  

  • 35. [Fixed drug erythema with mucosal involvement. An overlooked diagnosis?].
    Laurberg G; Christiansen JV
    Ugeskr Laeger; 1985 Jun; 147(23):1853-4. PubMed ID: 3161235
    [No Abstract]   [Full Text] [Related]  

  • 36. Topical provocation of fixed drug eruption.
    Alanko K; Stubb S; Reitamo S
    Br J Dermatol; 1987 Apr; 116(4):561-7. PubMed ID: 2953388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct oral provocation tests in non-immediate mild cutaneous reactions related to beta-lactam antibiotics.
    Vezir E; Dibek Misirlioglu E; Civelek E; Capanoglu M; Guvenir H; Ginis T; Toyran M; Kocabas CN
    Pediatr Allergy Immunol; 2016 Feb; 27(1):50-4. PubMed ID: 26619970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-induced hypersensitivity syndrome in pediatric patients.
    Carroll MC; Yueng-Yue KA; Esterly NB; Drolet BA
    Pediatrics; 2001 Aug; 108(2):485-92. PubMed ID: 11483822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contact sensitivity to oxyphenbutazone (Tanderil) and cross-sensitivity to phenylbutazone (Butazolidin).
    Krook G
    Contact Dermatitis; 1975 Aug; 1(4):262. PubMed ID: 139243
    [No Abstract]   [Full Text] [Related]  

  • 40. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions.
    Barbaud A; Gonçalo M; Bruynzeel D; Bircher A;
    Contact Dermatitis; 2001 Dec; 45(6):321-8. PubMed ID: 11846746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.